For the quarter ending 2025-09-30, PRCT had -$8,436K decrease in cash & cash equivalents over the period. -$9,503K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -21,411 | -44,316 |
| Depreciation and amortization | 1,618 | 3,063 |
| Stock-based compensation expense | 14,490 | 22,271 |
| Change in fair value of derivative liability | 0 | 0 |
| Non-cash lease adjustment | 127 | 254 |
| Inventory write-down | 76 | 490 |
| Provision for credit losses | 526 | 900 |
| (gain) loss on foreign currency transactions | -227 | 348 |
| Accounts receivable, net | 4,351 | -1,223 |
| Inventory | -568 | 11,068 |
| Prepaid expenses and other current assets | 1,760 | -1,089 |
| Other assets | 808 | 1,165 |
| Accounts payable | -789 | 1,504 |
| Accrued compensation | 5,455 | -5,248 |
| Accrued interest expense | 42 | 52 |
| Loan facility liability | -2,000 | - |
| Deferred revenue | 1,129 | 223 |
| Reimbursements for leasehold improvements from operating leases | 0 | 0 |
| Loan facility liability | - | -2,000 |
| Other liabilities | -1,520 | 1,561 |
| Net cash used in operating activities | -6,635 | -32,023 |
| Purchases of property and equipment | 2,868 | 4,638 |
| Net cash used in investing activities | -2,868 | -4,638 |
| Proceeds from issuance of common stock from the exercise of stock options | 1,078 | 2,171 |
| Proceeds from issuance of common stock under employee stock purchase plan | -1 | 3,505 |
| Net cash provided by financing activities | 1,077 | 5,676 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -10 | -23 |
| Net decrease in cash, cash equivalents and restricted cash | -8,436 | -31,008 |
| Cash and cash equivalents at beginning of period | 336,763 | - |
| Cash and cash equivalents at end of period | 297,319 | - |
PROCEPT BioRobotics Corp (PRCT)
PROCEPT BioRobotics Corp (PRCT)